• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: pharmacology

Antibiotics in infancy linked to higher asthma and food allergy risk

Antibiotics in infancy linked to higher asthma and food allergy risk

, 24 April 2025/in E-News, pharmacology, Research /by panglobal

A large-scale study from Rutgers Health has found that repeated antibiotic exposure in children under two years of age is associated with a significantly higher risk of developing asthma, food allergies and hay fever later in childhood. The research, involving over one million children, demonstrates that antibiotics may disrupt the digestive microbiome during a critical […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2025/04/antibiotics_24.jpg 640 960 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2025-04-24 07:30:392025-04-24 07:30:39Antibiotics in infancy linked to higher asthma and food allergy risk

AI system designs peptides to target previously ‘undruggable’ proteins

, 16 February 2025/in AI, E-News, pharmacology /by panglobal

Biomedical engineers at Duke University have developed an artificial intelligence platform that can design short proteins capable of binding to and destroying previously untreatable disease-causing proteins. The breakthrough could revolutionise drug development for currently intractable diseases.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2025/02/PepPrCLIP.jpeg 1106 1779 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2025-02-16 06:00:422025-02-06 07:05:36AI system designs peptides to target previously ‘undruggable’ proteins
MIT Microjet

Novel squid-inspired gastrointestinal capsule enables macromolecular drug delivery

capsule, drug delivery, needle-free, 20 November 2024/in Drug delivery, E-News, pharmacology /by panglobal

MIT and Novo Nordisk researchers have developed an ingestible capsule system that could enable oral delivery of medications typically requiring injection, such as insulin and therapeutic proteins. The needle-free device uses a biomimetic jet propulsion mechanism inspired by cephalopod physiology.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/11/MIT-Microjet-01-press.jpg 1600 2400 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-11-20 18:05:222024-11-19 11:19:21Novel squid-inspired gastrointestinal capsule enables macromolecular drug delivery
CAR-T therapy

New research reveals severe non-inflammatory neurological complications in young patients following CAR-T therapy

CAR-T therapy, side-effects, 10 October 2024/in E-News, Oncology, Patient Safety, pharmacology, Research /by panglobal

A study from Children’s Hospital of Philadelphia has uncovered rare but severe neurological side effects in children, adolescents, and young adults receiving CAR-T cell therapy for leukaemia, highlighting the need for further investigation into the complex mechanisms underlying these complications.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/10/CAR-T.jpg 706 978 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-10-10 08:00:122024-10-09 08:18:23New research reveals severe non-inflammatory neurological complications in young patients following CAR-T therapy
donanemab Kinsula

FDA under fire: Controversial Alzheimer’s drug donanemab approved amid excess death concerns and conflicts of interest

Alzheimer’s, donanemab, Eli Lilly, FDA, The BMJ, 26 September 2024/in dementia, E-News, Editors' Picks, Featured Articles, Patient Safety, pharmacology, Regulation /by panglobal

A new investigation of FDA-approved Alzheimer’s drug donanemab highlights concerns about excess deaths, missing safety data, and financial conflicts of interest among FDA advisory panel members who recommended approval.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/09/donanemab_kinsula_web.jpg 800 1200 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-09-26 02:00:412024-09-25 13:29:05FDA under fire: Controversial Alzheimer’s drug donanemab approved amid excess death concerns and conflicts of interest
Alzheimer’s disease

New Alzheimer’s drugs may have limited population-level impact, researchers warn

Alzheimer’s, clinical trials, donanemab, efficacy, lecanemab, 6 August 2024/in dementia, E-News, pharmacology /by panglobal

Cambridge scientists question whether recently approved amyloid immunotherapy treatments for Alzheimer’s disease will significantly reduce the condition’s burden, citing concerns about efficacy, safety, and health system challenges.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/08/alzheimers-disease-meds.jpg 739 1108 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-08-06 13:10:462024-08-05 13:41:26New Alzheimer’s drugs may have limited population-level impact, researchers warn

Latest issue of International Hospital

April 2024

28 April 2025

New study reveals TCAR outperforms TF-CAS for stroke prevention in carotid artery stenosis

28 April 2025

Study reveals stark socioeconomic gaps in mental health care access across EU

25 April 2025

Diabetes crisis deepens: 252 million unaware of condition as IDF recognises new type 5 diabetes

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription